Multifunctional nanosized peptide/glycopeptide conjugates as fully-synthetic vaccine for tumor-immunotherapy (B13)

• Subject Area: Immunology
• Term: since 2017
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 213555243

TP B13 established a modular vaccine platform using molecular (glyco)peptide building blocks. These carry tumor-associated antigens or immuno-stimulatory components and co-assemble into anisotropic multifunctional nanorods. The platform was successfully applied as fully synthetic vaccines against tumor-associated Mucin 1 during the previous funding period and will now be used to develop vaccines against malignant melanoma. Synthetic B-cell epitopes derived from melanoma associated surface protein CSPG4 will be co-presented on the nanorod surface, with T-cell epitopes and immunomodulating agents, and will be evaluated in vivo in terms of tumor-specific antibody induction and therapeutic effect.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1066: Nano-Dimensional Polymer Therapeutics for Tumour Therapy
• Applicant Institution: Johannes Gutenberg-Universität Mainz
• Project Heads: Professor Dr. Pol Besenius; Professor Dr. Tobias Bopp; Professor Dr. Edgar Schmitt, until 6/2021